Key result
Intracoronary eMSCs improve post-AMI LVEF by ~9 points in a porcine model.
RCT (n=69)
Randomized
Answers are grounded in this paper and cite their sources.
BACKGROUND: Engraftment and survival of stem cells in the infarcted myocardium remain problematic in cell-based therapy for cardiovascular disease. To overcome these issues, encapsulated mesenchymal stem cells (eMSCs) were developed that were transfected to produce glucagon-like peptide-1, an incretin hormone with known cardioprotective effects, alongside MSC endogenous paracrine factors. This study was designed to investigate the efficacy of different doses of intracoronary infusion of eMSC in a porcine model of acute myocardial infarction (AMI). METHODS AND RESULTS: One hundred pigs were subjected to a moderate AMI (posterolateral AMI; n=50) or a severe AMI (anterior AMI; n=50), whereupon surviving animals (n=36 moderate, n=33 severe) were randomized to receive either intracoronary infusion of 3 incremental doses of eMSC or Ringers' lactate control. Cardiac function was assessed using invasive hemodynamics, echocardiography, and histological analysis. A trend was observed in the moderate AMI model, whereas in the severe AMI model, left ventricular ejection fraction improved by +9.3% (P=0.004) in the best responding eMSC group, because of a preservation of left ventricular end-systolic volume. Arteriolar density increased 3-fold in the infarct area (8.4±0.9/mm(2) in controls versus 22.2±2.6/mm(2) in eMSC group; P<0.001). Although not statistically significant, capillary density was 30% higher in the border zone (908.1±99.7/mm(2) in control versus 1209.0±64.6/mm(2) in eMSC group; P=ns). CONCLUSIONS: eMSCs enable sustained local delivery of cardioprotective proteins to the heart, thereby enhancing angiogenesis and preserving contractile function in an animal AMI model.
No takes yet. Share an insight, caveat, or question.
Jong et al. (2014) conducted an RCT in Acute Myocardial Infarction (n=69). Encapsulated mesenchymal stem cells (eMSCs) producing glucagon-like peptide-1 vs. Ringers' lactate control was evaluated on Left ventricular ejection fraction in the severe AMI model (+9.3% improvement, p=0.004). Intracoronary infusion of eMSCs in a severe porcine AMI model improved left ventricular ejection fraction by 9.3% and increased arteriolar density 3-fold.
Synapse has enriched 10 related papers. Consider them for comparative context: